Kane Biotech Inc V.KNE

New Press Release - Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March...read article.

[francoisl13]

As expected (hoped...), the STEM deal is very likely going to be signed before the end of March. It is pretty obvious, when considerng the amount of money paid upfront (and deductible from the STEM sales value) that this is moving forward. So far KNE got 1.5M in 'upfront payments'....from past discussions with various people, expectations for the sales of the STEM division were ranging

[francoisl13]

One thing I forgot to mention is my previous posts is that it will be interesting to know if KNE keeps the patents/IP related to the animal health biofilm applications and ultimately gets some license fees from the STEM buyer and their potential clients. I hope this will be clarified when they make the sales annoucements.

[RoyMax123]

I would rather like to see them selling the right to use their tech in any animal products for a good chunk of money. Because they will need more than 6-11M to clear the debt and run the business for several months since revyve will take some time to be profitable. 

[francoisl13]

Interesting point of view. For my part, I'd rather keep the lower licensee fees for years to come and do my best to make sure Revyve sales pick-ups and covers expenses until a 2nd product comes to the market (ie.: gel spray, dermaKB, etc...). I think the decision to sell or not the animal health related IP will depend on where they stand in regards to Revyve market penetration and 2024-256

[mjh9413]

That is a question I asked them in an email when the non-bimding deal was announced..."how do they protect their patents (and they are used across a multiple of products ),and do they get ongoing royalties from the Stem buyer" No answer.

[francoisl13]

I wonder if they will 'halt' trading tomorrow before the market opens... To me, selling the STEM Animal division is big enough that it is worth a trading halt.  Will see GLTA

[RoyMax123]

Don't be surprise if they miss that new deadline...    BTW, the PIVOT extension was until yesterday so another missed deadline   BTW2 The Revyve scale-up production was supposed to be in Q1 so unless they forgot to announce it, it's another missed deadline.  

[francoisl13]

Yup, I hear you RouMax123...they are known for missing their own deadline. You forgot to mention the acne trial and starts of phase 1 with DispersinB. They are for the most part always a "little too' optimistic or they don't fully understand the time required to achieve their different goals/targets. I'm suspecting them to hold on some news like the Pivot and Revyve ones because